Cor Integrilin
Executive Summary
FDA approves supplemental indication for eptifibatide June 8 for patients with acute coronary syndrome, including those undergoing percutaneous coronary intervention. Approval is based on data from Cor's ESPRIT trial (1"The Pink Sheet" Jan. 15, p. 7)